Abstract
The expiration of patent protection and the subsequent sharp decline in sales have become a crucial topic for many pharmaceutical companies in recent years. The effort invested in designing strategies to cushion the adverse effects of patent expiry has increased considerably. One strategy, the launch of a second brand with a lower price, is frequently discussed as a potentially promising new option but has rarely been implemented. This contribution focuses on this fighter-brand strategy, its strengths and weaknesses and compares it to other pricing strategies. Moreover, it provides a detailed analysis of a major case example where a fighter brand was launched, the patent expiry of Zocor in Germany.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
